51 completed, 5 terminated, 1 approved for marketing, 1 withdrawn. 19 Phase 2, 14 Phase 1, 12 Phase 3, 7 Phase 4, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 16, Terminated 3 |
| Phase 1 | 14 | Completed 14 |
| Phase 3 | 12 | Completed 12 |
| Phase 4 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
| Not applicable | 3 | Completed 3 |
Follow etravirine: new trials by email Literature Review of etravirine trials Research Report on etravirine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR) - HIV Infections | Phase 1 | Completed | ViiV Healthcare | 54 | 2020-10-28 | 2024-08-29 |
| Safety and Efficacy of Etravirine in Friedreich Ataxia Patients Etravirine Tablets - Friedreich Ataxia | Phase 2 | Completed | IRCCS Eugenio Medea | 30 | 2020-09-17 | 2024-12-04 |
| A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants JNJ-64417184, Itraconazole, Etravirine - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 32 | 2019-12-20 | 2025-02-03 |
| Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients darunavir/cobicistat, etravirine - HIV-1 Infection | Phase 1 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 30 | 2016-06-01 | 2018-03-12 |
| Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL raltegravir and etravirine - HIV-1 Infection | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 170 | 2015-01-01 | 2026-04-03 |
| Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy triple therapy, dual therapy - HIV | Phase 3 | Completed | University Hospital, Tours | 224 | 2014-12-01 | 2025-12-26 |
| 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients Four consecutive days on treatment and 3 days off - HIV-1 Infection | Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 100 | 2014-07-01 | 2016-01-27 |
| DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV) BMS-663068, Darunavir (DRV), Ritonavir (RTV) - Infection, Human Immunodeficiency Virus | Phase 1 | Completed | ViiV Healthcare | 42 | 2014-02-01 | 2017-08-08 |
| Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children Etravirine (ETR) - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 26 | 2013-03-14 | 2021-11-02 |
| A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure Darunavir, Etravirine, Emtricitabine/tenofovir disoproxil fumarate - HIV-1 Infection | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 545 | 2013-02-22 | 2019-03-15 |
| An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients darunavir (PREZISTA), etravirine (INTELENCE), ritonavir - Human Immunodeficiency Virus (HIV) | Completed | Janssen Inc. | 77 | 2011-10-01 | 2014-05-22 | |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients Etravirine - Human Immunodeficiency Virus (HIV) Infection | Phase 4 | Completed | Janssen R&D Ireland | 211 | 2011-09-01 | 2014-10-13 |
| Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers boceprevir; etravirine - Hepatitis C, HIV | Not applicable | Completed | University of Colorado, Denver | 26 | 2011-08-01 | 2013-07-09 |
| Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine Etravirine, Darunavir/ritonavir, artemether/lumefantrine - HIV | Phase 1 | Completed | Janssen Pharmaceutica N.V., Belgium | 33 | 2011-03-01 | 2013-06-13 |
| A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022 lersivirine, efavirenz, etravirine - HIV-1 | Phase 2 | Terminated | Pfizer | 108 | 2011-02-01 | 2014-06-09 |
| Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine - Infection, Human Immunodeficiency Virus | Phase 2 | Terminated | ViiV Healthcare | 30 | 2010-10-05 | 2017-11-17 |
| The First Failure Study Darunavir, Ritonavir, Truvada, Darunavir, Ritonavir and Etravirine - HIV, HIV Infections | Phase 4 | Terminated | Imperial College London | 3 | 2010-05-01 | 2015-03-24 |
| A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients Etravirine, Ritonavir, Darunavir - Human Immunodeficiency Virus (HIV) | Phase 2 | Completed | Tibotec, Inc | 54 | 2010-05-01 | 2013-12-04 |
| Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily Raltegravir, Etravirine - HIV-1 Infection, HIV Infections | Phase 4 | Completed | Hospitales Universitarios Virgen del Rocío | 16 | 2010-04-01 | 2011-02-08 |
| TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients etravirine - HIV-Infections | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 49 | 2010-03-01 | 2012-12-11 |
Showing 20 of 58. Sign in to see all of them.
HIV Infections (27) · Acquired Immunodeficiency Syndrome (17) · Infections (4) · AIDS Dementia Complex (1) · Anxiety Disorders (1) · Cognitive Dysfunction (1) · Coitus (1) · Depression (1) · Disorders of Excessive Somnolence (1) · Friedreich Ataxia (1) · Hepatitis B (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Inflammation (1) · Insulin Resistance (1)
Tibotec Pharmaceuticals, Ireland (14) · ViiV Healthcare (5) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Tibotec, Inc (3) · University of North Carolina, Chapel Hill (3) · ANRS, Emerging Infectious Diseases (2) · Janssen R&D Ireland (2) · Pfizer (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · Germans Trias i Pujol Hospital (1) · GlaxoSmithKline (1) · Hospitales Universitarios Virgen del Rocío (1) · IRCCS Eugenio Medea (1)
United States (29) · Puerto Rico (12) · France (11) · Spain (10) · Brazil (9) · South Africa (9) · Canada (8) · Argentina (7) · Thailand (7) · United Kingdom (6) · Mexico (5) · Romania (5) · Belgium (4) · Germany (4) · Italy (4)
Kristine B Patterson, MD (2) · Alan Winston, MB ChB (1) · Angela DM Kashuba, PharmD (1) · Beatriz Grinsztejn, MD, PhD (1) · Bernard BH Hirschel, Professor (1) · Christine Katlama, MD (1) · Cynthia Gay, MD, MPH (1)
PMID 19710593, PMID 20507207, PMID 20801782, PMID 20881958, PMID 16470119, PMID 16988514, PMID 17617270, PMID 17617271, PMID 18366444, PMID 18764771, PMID 18795960, PMID 18795962, PMID 18989231, PMID 19114852, PMID 20002783, PMID 20632458, PMID 20710052, PMID 20827162, PMID 20939732, PMID 21150563, PMID 21283017, PMID 21881478, PMID 22083071, PMID 22129166, PMID 22190606, PMID 22210755, PMID 23305215, PMID 23392467, PMID 23400742, PMID 23441978, PMID 24352352, PMID 24503952, PMID 25162818, PMID 25261418, PMID 25397527, PMID 25407158, PMID 25585528, PMID 25950206, PMID 25959631, PMID 26202768, PMID 26263403, PMID 26566161, PMID 26595748, PMID 26918544, PMID 27540363, PMID 27583590, PMID 29186458, PMID 29335895, PMID 29369162, PMID 29520730
2009 (2), 2014 (2), 2019 (2), 2008 (1), K23AI077355 (1), R01MH058076 (1), U01AI068632 (1), U01AI068636 (1)